| Literature DB >> 34414517 |
Adnan Noor Baloch1, Mats Hagberg2, Sara Thomée3, Gunnar Steineck4, Helena Sandén2.
Abstract
PURPOSE: Gynaecological cancer patients treated with external radiation therapy to the pelvis may face long-lasting and long-term gastrointestinal syndromes. The aim of this study was to assess the association between such radiation-induced survivorship syndromes and disability pension among gynaecological cancer survivors treated with pelvic radiation therapy.Entities:
Keywords: Cancer survivor; Disability pension; Faecal incontinence; Radiation-induced syndromes; Radiotherapy/adverse effects; Return to work
Mesh:
Year: 2021 PMID: 34414517 PMCID: PMC9300541 DOI: 10.1007/s11764-021-01077-9
Source DB: PubMed Journal: J Cancer Surviv ISSN: 1932-2259 Impact factor: 4.062
Baseline clinical and demographic data for all gynaecological cancer survivors and for gynaecological cancer survivors with and without syndromes
| All survivors | Gynaecological survivors with | Urgency syndrome | Leakage syndrome | Blood discharge syndrome | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No syndrome | One syndrome | Two syndromes | Three syndromes | Yes | No | Yes | No | Yes | No | ||
| n=247 | n=131 (53 %)a | n=50 (20%)a | n=49 (20%)a | n=17 (7 %)a | n=91 (37 %)a | n=156 (63 %) a | n=77 (31 %) a | n=170 (69 %)a | n=31 (13 %)a | n=216 (87 %)a | |
| No. (%)b | No. (%)b | No. (%)b | No. (%)b | No. (%)b | No. (%)b | No. (%)b | No. (%)b | No. (%)b | No. (%)b | No. (%)b | |
| Age | |||||||||||
| 16–29 years | 2 (1 %) | 0 | 2 (4 %) | 0 | 0 | 2 (2 %) | 0 | 0 | 2 (1 %) | 0 | 2 (1 %) |
| 30–49 years | 66 (27 %) | 36 (27 %) | 13 (26 %) | 14 (29 %) | 3 (18 %) | 24 (26 %) | 42 (27 %) | 19 (25 %) | 47 (28 %) | 7 (23 %) | 59 (27 %) |
| 50–64 years | 179 (72 %) | 95 (73 %) | 35 (70 %) | 35 (71 %) | 14 (82 %) | 65 (71 %) | 114 (73 %) | 58 (75 %) | 121 (71 %) | 24 (77 %) | 155 (72 %) |
| Self-reported employment status | |||||||||||
| Employed | 169 (69 %) | 100 (77 %) | 33 (69 %) | 28 (57 %) | 8 (47 %) | 54 (59 %) | 115 (75 %) | 43 (57 %) | 126 (75 %) | 16 (53 %) | 153 (72 %) |
| Disability pension | 35 (14 %) | 10 (8 %) | 5 (10 %) | 14 (29 %) | 6 (35 %) | 22 (24 %) | 13 (9 %) | 20 (26 %) | 15 (9 %) | 9 (30 %) | 26 (12 %) |
| Unemployed | 12 (5%) | 7 (5 %) | 2 (4 %) | 2 (4 %) | 1 (6 %) | 3 (3 %) | 9 (6 %) | 4 (5 %) | 8 (5 %) | 2 (7 %) | 10 (5 %) |
| Housewife, other | 10 (4 %) | 5 (4 %) | 2 (4 %) | 2 (4 %) | 1 (6 %) | 3 (3 %) | 7 (5 %) | 5 (7 %) | 5 (3 %) | 1 (3 %) | 9 (4 %) |
| Sickness absence | 9 (4 %) | 2 (2 %) | 5 (10 %) | 2 (4 %) | 0 | 7 (8 %) | 2 (1 %) | 1 (1 %) | 8 (5 %) | 1 (3 %) | 8 (4 % ) |
| Student | 5 (2 %) | 3 (2 %) | 0 | 1 (2 %) | 1 (6 %) | 2 (2 %) | 3 (2 %) | 2 (3 %) | 3 (2 %) | 1 (3 %) | 4 (2 %) |
| Retired | 4 (2 %) | 3 (2 %) | 1 (2 %) | 0 | 0 | 0 | 4 (3 %) | 1 (1 %) | 3 (2 %) | 0 | 4 (2 %) |
| Not stated | 3 | 1 | 2 | 0 | 0 | 3 | 1 | 2 | 1 | 2 | |
| Diagnosis | |||||||||||
| Endometrial cancer | 104 (42 %) | 57 (44 %) | 24 (48 %) | 19 (39 %) | 4 (24 %) | 38 (42 %) | 66 (42 %) | 27 (35 %) | 77 (45 %) | 9 (29 %) | 95 (44 %) |
| Cervical cancer | 93 (38 %) | 52 (40 %) | 17 (34 %) | 18 (37 %) | 6 (35 %) | 33 (36 %) | 60 (38 %) | 27 (35 %) | 66 (39 %) | 11 (35 %) | 82 (38 %) |
| Ovarian cancer | 23 (9 %) | 10 (8 %) | 3 (6 %) | 8 (16 %) | 2 (12 %) | 10 (11 %) | 13 (8 %) | 11 (14 %) | 12 (7 %) | 4 (13 %) | 19 (9 %) |
| Vaginal cancer | 11 (4 %) | 4 (3 %) | 3 (6 %) | 1 (2 %) | 3 (18 %) | 4 (4 %) | 7 (4 %) | 5 (6 %) | 6 (4 %) | 5 (16 %) | 6 (3 %) |
| Sarcoma uteri | 9 (4 %) | 5 (4 %) | 2 (4 %) | 2 (4 %) | 0 | 3 (3 %) | 6 (4 %) | 3 (4 %) | 6 (4 %) | 0 | 9 (4 %) |
| Fallopian tube cancer | 5 (2 %) | 2 (2 %) | 1 (2 %) | 1 (2 %) | 1 (6 %) | 2 (2 %) | 3 (2 %) | 3 (4 %) | 2 (1 %) | 1 (3 %) | 4 (2 %) |
| Vulvar cancer | 2 (1 %) | 1 (1 %) | 0 | 0 | 1 (6 %) | 1 (1 %) | 1 (1 %) | 1 (1 %) | 1 (1 %) | 1 (3 %) | 1 (1 %) |
| Treatment modality | |||||||||||
| Surgery + EBRTc + BTd | 110 (45 %) | 66 (51 %) | 23 (46 %) | 18 (37 %) | 3 (18 %) | 35 (38 %) | 75 (48 %) | 24 (31 %) | 86 (51 %) | 9 (29 %) | 101 (47 %) |
| Surgery + EBRTc + BTd + Chemoe | 56 (23 %) | 30 (23 %) | 17 (34 %) | 5 (10 %) | 4 (24 %) | 18 (20 %) | 38 (25 %) | 15 (19 %) | 41 (24 %) | 6 (19 %) | 50 (23 %) |
| Surgery + EBRTc + Chemoe | 28 (11 %) | 11 (8 %) | 4 (8 %) | 9 (18 %) | 4 (24 %) | 14 (15 %) | 14 (9 %) | 15 (19 %) | 13 (8 %) | 5 (16 %) | 23 (11 %) |
| Surgery + EBRTc | 18 (7 %) | 7 (5 %) | 4 (8 %) | 5 (10 %) | 2 (12 %) | 8 (9 %) | 10 (6 %) | 7 (9 %) | 11 (7 %) | 5 (16 %) | 13 (6 %) |
| EBRTc + BTd + Chemoe | 17 (7 %) | 11 (8 %) | 1 (2 %) | 5 (10 %) | 0 | 5 (5 %) | 12 (8 %) | 4 (5 %) | 13 (8 %) | 2 (6 %) | 15 (7 %) |
| EBRTc + BTd | 11 (4 %) | 5 (4 %) | 1 (2 %) | 4 (8 %) | 1 (6 %) | 5 (5 %) | 6 (4 %) | 6 (8 %) | 5 (3 %) | 1 (3 %) | 10 (5 %) |
| EBRTc + Chemoe | 5 (2 %) | 0 | 0 | 3 (6 %) | 2 (12 %) | 5 (5 %) | 0 | 5 (6 %) | 0 | 2 (6 %) | 3 (1 %) |
| EBRTc | 1 (<1 %) | 0 | 0 | 0 | 1 (6 %) | 1 (1 %) | 0 | 1 (1 %) | 0 | 1 (3 %) | 0 |
| Not stated | 1 | 1 | 1 | 1 | |||||||
| Parity | |||||||||||
| Never given birth | 80 (32 %) | 47 (36 %) | 14 (28 %) | 15 (31 %) | 4 (24 %) | 27 (30 %) | 53 (34 %) | 21 (27 %) | 59 (35 %) | 8 (26 %) | 72 (33 %) |
| 1–3 children | 151 (61 %) | 77 (59 %) | 32 (64 %) | 31 (63 %) | 11 (65 %) | 56 (62 %) | 95 (61 %) | 52 (68 %) | 99 (58 %) | 19 (61 %) | 132 (61 %) |
| > 3 children | 16 (6 %) | 7 (5 %) | 4 (8 %) | 3 (6 %) | 2 (12 %) | 8 (9 %) | 8 (5 %) | 4 (5 %) | 12 (7 %) | 4 (13 %) | 12 (6 %) |
aNumber (percentage) within each category of syndrome
bNumber and percentage of survivors in each category
EBRTc denotes external beam radiation therapy
BTd denotes brachytherapy
Chemoe denotes chemotherapy
Figure 1.Number (percentage) and relative risk (RR) (95% confidence interval) of disability pension (data taken from the official register) at the 2-year follow-up. Relative risks (CIs) obtained from log-binomial regression analyses using syndromes as a predictor. Self-reported symptoms were used to classify survivors having a syndrome. A relative risk of > 1 indicates harm (No. = number)
Unadjusted relative risks (RRs) and risk differences (RDs) (95% confidence intervals (CIs)) for disability pension (from the national register on disability pension) among survivors with one or more syndromes
| Disability pension at 2-year follow-up | ||||
|---|---|---|---|---|
| Relative risksa (95 % CI) | Risk differences b (95% CI) | |||
| Syndromesc | n = 247d | n = 243e | n = 247d | n = 243e |
| Sum of syndromesf | ||||
| Three syndromes vs none | ||||
| Two syndromes vs none | ||||
| One syndrome vs None | 1.2 (0.6 to 2.3) | 1.2 (0.7 to 2.4) | 4% (-10% to 17%) | 4% (-9% to 18%) |
| Urgency vs no urgency syndrome | ||||
| Leakage vs no leakage syndrome | ||||
| Blood vs no blood discharge syndrome | ||||
| Excessive gas vs no excessive gas discharge syndrome | 1.5 (1.0 to 2.3) | 1.5 (1.0 to 2.3) | 12 % (−2% to 26%) | 12 % (−2% to 27%) |
| Excessive mucus vs no excessive mucus discharge syndrome | 1.0 (0.6 to 1.6) | 1.0 (0.6 to 1.6) | 0 % (−13% to 13%) | 0 % (−13% to 13%) |
a,bUnadjusted RR and RD (95% CI) obtained from log-binomial regression analyses using only a Syndrome as a predictor with ‘None/No’ level used as a reference
cSelf-reported symptoms were used to build syndrome
dSurvivors alive at follow-up in 2008
eExcluding survivors who died within the 2-years of follow-up (between 2008 and 2010)
fSurvivors classified as having several syndromes or one or none. Bold numbers indicate a statistically significant association at 5% level of significance